Fig. 1From: Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemiaa) The trend of quantitative BCR-ABL1 transcript levels by PCR over initial 12 months of therapy by transcript type. b) The number of patients meeting optimal ELN criteria by transcript type at each timepoint in year 1. EXC CHANGER = excludes patients changing TKI therapy prior to 12 months * = p value < 0.05Back to article page